[96a5a0]: / output / allTrials / identified / NCT01394991_identified.json

Download this file

418 lines (418 with data), 20.5 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
{
"info": {
"nct_id": "NCT01394991",
"official_title": "A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia",
"inclusion_criteria": "* Any nonmyeloid tumor confirmed by cytology and/or histology\n* Day 1 baseline hemoglobin (Hb) level <=11 g/dL\n* Expected to receive at least 12 weeks of chemotherapy after enrollment into the study\n* Eastern Cooperative Oncology Group (ECOG) performance status <= 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* History of active second cancer except for adequately treated skin cancer and in situ (pre-invasive) cervical cancer\n* History of deep venous thrombosis (DVT) (blood clots in the veins of the thighs or legs) or pulmonary embolism (PE) (blood clot in the lungs) within 12 months before study entry or at any time if the event is related to the current cancer, which is defined as diagnosis of the cancer within 3 months of a DVT/PE episode or a DVT/PE following the cancer diagnosis/treatment\n* History of cardiovascular accident (CVA), transient ischemic attack (TIA) (stroke), acute coronary syndrome (ACS) (a condition indicating damage to the heart), or other arterial thrombosis (blood clots) within 6 months before study entry\n* Onset of seizures within 3 months before randomization or poorly controlled seizures\n* Brain tumor or brain metastasis from another malignancy or cardiac disease that is markedly or completely limiting, uncontrolled hypertension (high blood pressure), or anemia (a lack of red blood cells in the blood) for reasons other than cancer or chemotherapy\n* Specifically excluded concomitant medications or therapies including prophylactic anticoagulation therapy for recurrence of prior thrombovascular event (TVE) (warfarin, unfractionated heparin, low molecular weight heparin [LMWH], except for prevention of central venous catheter thrombosis at doses specified in the protocol, direct thrombin inhibitors, or anti-platelet drugs [e.g., clopidogrel or ticlopidine]), except for prophylaxis in patients with known cardiovascular disease",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Any nonmyeloid tumor confirmed by cytology and/or histology",
"criterions": [
{
"exact_snippets": "nonmyeloid tumor confirmed by cytology and/or histology",
"criterion": "nonmyeloid tumor",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"cytology",
"histology"
]
}
]
}
]
},
{
"line": "* Day 1 baseline hemoglobin (Hb) level <=11 g/dL",
"criterions": [
{
"exact_snippets": "Day 1 baseline hemoglobin (Hb) level <=11 g/dL",
"criterion": "hemoglobin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 11,
"unit": "g/dL"
}
}
]
}
]
},
{
"line": "* Expected to receive at least 12 weeks of chemotherapy after enrollment into the study",
"criterions": [
{
"exact_snippets": "Expected to receive at least 12 weeks of chemotherapy",
"criterion": "chemotherapy duration",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status <= 2",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status <= 2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "performance status",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* History of active second cancer except for adequately treated skin cancer and in situ (pre-invasive) cervical cancer",
"criterions": [
{
"exact_snippets": "History of active second cancer",
"criterion": "active second cancer",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "except for adequately treated skin cancer",
"criterion": "adequately treated skin cancer",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "adequately treated"
}
]
},
{
"exact_snippets": "except for ... in situ (pre-invasive) cervical cancer",
"criterion": "in situ cervical cancer",
"requirements": [
{
"requirement_type": "invasiveness",
"expected_value": "pre-invasive"
}
]
}
]
},
{
"line": "* History of cardiovascular accident (CVA), transient ischemic attack (TIA) (stroke), acute coronary syndrome (ACS) (a condition indicating damage to the heart), or other arterial thrombosis (blood clots) within 6 months before study entry",
"criterions": [
{
"exact_snippets": "History of cardiovascular accident (CVA) ... within 6 months before study entry",
"criterion": "cardiovascular accident (CVA)",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
]
},
{
"exact_snippets": "History of ... transient ischemic attack (TIA) (stroke) ... within 6 months before study entry",
"criterion": "transient ischemic attack (TIA)",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
]
},
{
"exact_snippets": "History of ... acute coronary syndrome (ACS) (a condition indicating damage to the heart) ... within 6 months before study entry",
"criterion": "acute coronary syndrome (ACS)",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
]
},
{
"exact_snippets": "History of ... other arterial thrombosis (blood clots) within 6 months before study entry",
"criterion": "arterial thrombosis",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Onset of seizures within 3 months before randomization or poorly controlled seizures",
"criterions": [
{
"exact_snippets": "Onset of seizures within 3 months before randomization",
"criterion": "seizure onset",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "poorly controlled seizures",
"criterion": "seizure control",
"requirements": [
{
"requirement_type": "control",
"expected_value": "poorly controlled"
}
]
}
]
},
{
"line": "* Brain tumor or brain metastasis from another malignancy or cardiac disease that is markedly or completely limiting, uncontrolled hypertension (high blood pressure), or anemia (a lack of red blood cells in the blood) for reasons other than cancer or chemotherapy",
"criterions": [
{
"exact_snippets": "Brain tumor",
"criterion": "brain tumor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "brain metastasis from another malignancy",
"criterion": "brain metastasis",
"requirements": [
{
"requirement_type": "origin",
"expected_value": "another malignancy"
}
]
},
{
"exact_snippets": "cardiac disease that is markedly or completely limiting",
"criterion": "cardiac disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "markedly or completely limiting"
}
]
},
{
"exact_snippets": "uncontrolled hypertension (high blood pressure)",
"criterion": "hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "anemia (a lack of red blood cells in the blood) for reasons other than cancer or chemotherapy",
"criterion": "anemia",
"requirements": [
{
"requirement_type": "cause",
"expected_value": "reasons other than cancer or chemotherapy"
}
]
}
]
},
{
"line": "* Specifically excluded concomitant medications or therapies including prophylactic anticoagulation therapy for recurrence of prior thrombovascular event (TVE) (warfarin, unfractionated heparin, low molecular weight heparin [LMWH], except for prevention of central venous catheter thrombosis at doses specified in the protocol, direct thrombin inhibitors, or anti-platelet drugs [e.g., clopidogrel or ticlopidine]), except for prophylaxis in patients with known cardiovascular disease",
"criterions": [
{
"exact_snippets": "Specifically excluded concomitant medications or therapies including prophylactic anticoagulation therapy for recurrence of prior thrombovascular event (TVE) (warfarin, unfractionated heparin, low molecular weight heparin [LMWH], ... direct thrombin inhibitors, or anti-platelet drugs [e.g., clopidogrel or ticlopidine])",
"criterion": "concomitant medications or therapies",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": [
"prophylactic anticoagulation therapy for recurrence of prior thrombovascular event (TVE)",
"warfarin",
"unfractionated heparin",
"low molecular weight heparin [LMWH]",
"direct thrombin inhibitors",
"anti-platelet drugs [e.g., clopidogrel or ticlopidine]"
]
}
]
},
{
"exact_snippets": "except for prevention of central venous catheter thrombosis at doses specified in the protocol",
"criterion": "prevention of central venous catheter thrombosis",
"requirements": [
{
"requirement_type": "exception",
"expected_value": true
}
]
},
{
"exact_snippets": "except for prophylaxis in patients with known cardiovascular disease",
"criterion": "prophylaxis in patients with known cardiovascular disease",
"requirements": [
{
"requirement_type": "exception",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* History of deep venous thrombosis (DVT) (blood clots in the veins of the thighs or legs) or pulmonary embolism (PE) (blood clot in the lungs) within 12 months before study entry or at any time if the event is related to the current cancer, which is defined as diagnosis of the cancer within 3 months of a DVT/PE episode or a DVT/PE following the cancer diagnosis/treatment",
"criterions": [
{
"exact_snippets": "History of deep venous thrombosis (DVT) ... within 12 months before study entry",
"criterion": "history of deep venous thrombosis (DVT)",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 12,
"unit": "months"
}
}
]
},
{
"exact_snippets": "History of deep venous thrombosis (DVT) ... at any time if the event is related to the current cancer",
"criterion": "history of deep venous thrombosis (DVT)",
"requirements": [
{
"requirement_type": "relation to current cancer",
"expected_value": true
}
]
},
{
"exact_snippets": "History of pulmonary embolism (PE) ... within 12 months before study entry",
"criterion": "history of pulmonary embolism (PE)",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 12,
"unit": "months"
}
}
]
},
{
"exact_snippets": "History of pulmonary embolism (PE) ... at any time if the event is related to the current cancer",
"criterion": "history of pulmonary embolism (PE)",
"requirements": [
{
"requirement_type": "relation to current cancer",
"expected_value": true
}
]
}
]
}
],
"failed_miscellaneous": []
}